Lumosa Therapeutics Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 14.21 million compared to TWD 4.91 million a year ago. Net loss was TWD 150.95 million compared to TWD 195.1 million a year ago. Basic loss per share from continuing operations was TWD 0.92 compared to TWD 1.2 a year ago. Diluted loss per share from continuing operations was TWD 0.92 compared to TWD 1.2 a year ago.
For the six months, sales was TWD 22.18 million compared to TWD 7.71 million a year ago. Net loss was TWD 5.62 million compared to TWD 379.65 million a year ago. Basic loss per share from continuing operations was TWD 0.03 compared to TWD 2.34 a year ago. Diluted loss per share from continuing operations was TWD 0.03 compared to TWD 2.34 a year ago.